• Incannex dosed the first patient in its DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea.
• Earlier Phase 2 RePOSA results have already been presented, showing meaningful improvement versus placebo with a favorable safety profile.
• DReAMzz aims to refine the treatment regimen and support dose selection for a planned Phase 3 program.
• FDA Fast Track status strengthens the regulatory path and could speed development timelines for IHL-42X.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-093244), on August 25, 2026, and is solely responsible for the information contained therein.